ライフサイエンスコーパス: weight decrease

1 cartilage damage, bone resorption, and body weight decrease.

2 xol((R)) resulted in toxicity issues as body weight decreased.

3 XR monotherapy showed sustained ALT and body weight decreases.

4 Weight decreased 0.2 lb in the intervention and increase

5 However, birth weights decreased (15% after one dose, 19% after two dos

6 s), diarrhoea (17 [9%]), asthenia (16 [8%]), weight decrease (16 [8%]), and PPE (14 [7%]); common gra

7 els, jawbone lengths, body weight, and organ weights decreased, 4) adult female imidacloprid levels i

8 ients), hypertension (92 [49%] vs 28 [29%]), weight decrease (69 [37%] vs 23 [24%]), decreased appeti

9 Weight decreased 8% (SEM, 1%) compared with 7% (SEM, 1%)

10 gluteal and iliac lymph nodes (maximum nodal weight decreases, 86% and 88% from control values, respe

11 ntile regression models indicated that birth weight decreased across the entire distribution, but red

12 n showed significant viscosity and molecular weight decrease after 1 week of oxidation at room temper

13 ts In the dietary group, fat intake and body weight decreased (all P < .001).

14 Hence, as body weight decreased and agouti-related protein is induced,

15 eeks of tirzepatide treatment, participants' weight decreased and cardiometabolic parameters improved

16 lative reliabilities of the two cues: visual weights decrease and vestibular weights increase when vi

17 Body weight decreased as expected after surgery.

18 f the traditional catalyst system, molecular weights decrease as the level of comonomer increases and

19 Initial weight decreased at least 5% in 21.5%, 26.0%, and 34.9%

20 71.9 mg/g during baking, but their molecular weight decreased at the beginning of the process and inc

21 MI trajectories were identified: "low-normal weight, decreasing" (baseline BMI = 18.7; 23.8% of sampl

22 ne BMI = 18.7; 23.8% of sample); "mid-normal weight, decreasing" (baseline BMI = 21.9; 44.6% of sampl

23 e BMI = 21.9; 44.6% of sample); "high-normal weight, decreasing" (baseline BMI = 24.8; 26.5% of sampl

24 ticular, relative to those with a mid-normal weight, decreasing BMI trajectory, those with an overwei

25 ncreased plasma estradiol, increased uterine weight, decreased body weight, decreased visceral adipos

26 Body weight decreased by 0.92 to 1.61 kg with dapagliflozin a

27 Weight decreased by 1.8 kg with exenatide and increased

28 Body weight decreased by 10% in the diet group and by 9% in t

29 In the WL group, body weight decreased by 10.2 +/- 5.5% (P < 0.001), body fat

30 acteristics, and pregnancy conditions, birth weight decreased by 2.20 g per year (P < 0.0001).

31 Body weight decreased by 2.8 kg (95% CI: -3.7 to -2.0) with d

32 emained active after water deprivation, body weight decreased by 20-22%, serum osmolality remained no

33 Body weight decreased by 35 +/- 2%, serum osmolality increase

34 intake decreased by 441 +/- 63 kcal/d, body weight decreased by 4.9 +/- 0.5 kg, and fat mass decreas

35 % upper confidence limit, 3.82), total stool weight decreased by 45.3 g (P = .37), and number of diar

36 Body weight decreased by 7% (7 kg [SD, 1]) in the diet group,

37 Body weight decreased by 8.4% (8.2 kg) in the treatment group

38 Body weight decreased by 9% in all exercise groups but did no

39 triction increased >6-fold, and infant birth weight decreased by approximately 200 g.

40 lution of hepatic yellow coloration; hepatic weight decreased by approximately 36% compared to PBS-tr

41 ysplasia, long bone length shortage and body weight decrease compared with wild-type littermates.

42 showed comparable anatomic (mean hemispheric weight decrease: control 42%, HPC 25% (P=0.01), HBO-PC 2

43 ents who had increased, stable, or decreased weight (decreased discharge dose from OOD dose in 77% ve

44 Specifically, females showed a marked weight decrease during the first week of isolation.

45 The brain weight decreases during aging in conjunction with severe

46 e, increased insulin sensitivity, lower body weight, decreased fat mass, and a complete reversal of h

47 The resulting effect was a lower body weight, decreased fat mass, and reduced leptin levels.

48 l-identified disabilities increased as birth weight decreased for all birth weight strata of <or=3,49

49 idal volume reported as mL/kg predicted body weight decreased from median 6.1 mL/kg (interquartile ra

50 The 18-month intervention resulted in weight decreasing from 93.1 kg (95% CI, 91.0 to 95.2 kg)

51 Potentially clinically significant weight decrease (>=7% reduction at any time post-baselin

52 e knockout seeds had approximately 3% of dry weight decrease in oil content compared with that of the

53 There was a significant fetal weight decrease in the IUGR FPUs (-21.9%; P < .001).

54 number of metals and ligands, the molecular weight decrease in the metal-rich area is caused by an i

55 The feces weight decreased in buserelin-treated rats (p < 0.01), w

56 or males (all P>0.44), although body fat and weight decreased in exposed females at particular ages (

57 Weight decreased in the demand group by 4.8 +/- 2.0 kg,

58 12:00 p.m. After the intervention, the body weight decreased in the EXP group (- 1.92 kg) with a 95%

59 er, increased patient age, increased patient weight, decreased injected activity, and increased (68)G

60 lic acid ratios as demonstrated by molecular weight decrease, lactic acid release, and thermal proper

61 Body weights decreased less than 10% in all groups.

62 ed liver and epididymal white adipose tissue weights, decreased liver adiposity, and improved hepatic

63 hing from TAF to TDF led to an adjusted mean weight decrease of -1.84 kg (95% CI -2.72 to -.97), and

64 initial 4 weeks of therapy, a mean absolute weight decrease of 0.4 kg was observed for all patients.

65 .66 to 1.37; I(2)=82%), and led to a greater weight decrease only when compared with a usual diet (ei

66 ragments (S-O-PG) (240 micrograms/kg of body weight) decreased overnight food consumption in male Lew

67 Body weight decreased (P < 0.001) by 5.6 +/- 1.0 kg (5.8 +/-

68 ed to increase their energy intakes as their weights decreased (p for trend < 0.002).

69 increased from 2- to 8-fold, adult prostate weight decreased relative to males exposed to the 50% in

70 Body weight decreased significantly (1.53 kg; P < 0.001) only

71 or African-American mothers only, mean birth weight decreased significantly as the neighborhood level

72 Patients' relative weight decreased significantly but only slightly, with t

73 inine ratio increased significantly and body weight decreased significantly in the bardoxolone methyl

74 By month 6, body weight decreased significantly in the TRE group (-3.56%

75 Body weight decreased significantly over a 6-mo intensive int

76 ther DOT1L or MLLT10 leads to reduced testis weight, decreased sperm count and male subfertility.

77 irus, as characterized by rapid loss of body weight, decreased survival time, and decreased mean leth

78 ary to determine whether a reduction in body weight decreases the risk of stone formation, particular

79 6.7+/-60.0 hrs, during which time their body weight decreased to 30%+/-12% above admission weight (p<

80 d; when digested with 100 U/gel, the gel wet weight decreased (to 57% of original wet weight versus 8

81 led to significantly reduced tumour size and weight, decreased tumour cell mitosis, and induced tumou

82 ol, increased uterine weight, decreased body weight, decreased visceral adiposity, and enhanced gluco

83 n the cold dried salami pH changes, a(w) and weight decrease were delayed; the phytocomplex contribut

84 Body weight decreased with liraglutide compared with placebo